{"id":59182,"date":"2026-03-10T16:25:29","date_gmt":"2026-03-10T08:25:29","guid":{"rendered":"https:\/\/flcube.com\/?p=59182"},"modified":"2026-03-10T16:25:30","modified_gmt":"2026-03-10T08:25:30","slug":"gsk-licenses-linerixibat-to-alfasigma-for-300-million-upfront-ibat-inhibitor-targets-pbc-pruritus-with-690-million-total-deal-value","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59182","title":{"rendered":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE:\u202fGSK<\/a>)<\/strong> and <strong>Alfasigma S.p.A.<\/strong> announced a <strong>licensing agreement<\/strong> granting Alfasigma <strong>exclusive global rights<\/strong> to <strong>linerixibat<\/strong>, an <strong>investigational ileal bile acid transporter (IBAT) inhibitor<\/strong> for <strong>cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC)<\/strong>. The deal delivers <strong>$300\u202fmillion upfront<\/strong> to GSK, with <strong>$100\u202fmillion FDA approval milestone<\/strong> anticipated <strong>pre-close<\/strong> (PDUFA date: March\u202f24,\u202f2026), and <strong>up to $690\u202fmillion total value<\/strong> including regulatory, sales milestones, and <strong>tiered double-digit royalties<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-structure\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><th>Trigger<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>$300\u202fmillion<\/td><td>Signing<\/td><\/tr><tr><td><strong>FDA Approval Milestone<\/strong><\/td><td>$100\u202fmillion<\/td><td>U.S. approval (expected pre-close; PDUFA March\u202f24,\u202f2026)<\/td><\/tr><tr><td><strong>EU\/UK Approval Milestone<\/strong><\/td><td>$20\u202fmillion<\/td><td>Regulatory clearance<\/td><\/tr><tr><td><strong>Sales-Based Milestones<\/strong><\/td><td>Up to $270\u202fmillion<\/td><td>Revenue thresholds<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered double-digit<\/td><td>Net global sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td><strong>~$690\u202fmillion<\/strong><\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Linerixibat Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Ileal bile acid transporter (IBAT) inhibitor<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>IBAT (apical sodium-dependent bile acid transporter)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks bile acid reuptake in terminal ileum \u2192 reduces circulating bile acid load<\/td><\/tr><tr><td><strong>Clinical Effect<\/strong><\/td><td>Reduces multiple pruritus mediators \u2192 alleviates cholestatic itch<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Cholestatic pruritus associated with primary biliary cholangitis (PBC)<\/td><\/tr><tr><td><strong>Route<\/strong><\/td><td>Oral, targeted therapy<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Debilitating pruritus in ~60% of PBC patients; inadequate response to ursodeoxycholic acid (UDCA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<p><strong>GSK Objectives:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Optimization:<\/strong> Divest non-core rare disease asset; focus resources on vaccines, infectious disease, respiratory<\/li>\n\n\n\n<li><strong>Value Realization:<\/strong> Monetize Phase III-ready program near regulatory inflection point<\/li>\n\n\n\n<li><strong>Risk Transfer:<\/strong> Alfasigma assumes commercial execution, manufacturing scale-up<\/li>\n<\/ul>\n\n\n\n<p><strong>Alfasigma Strategy:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare Disease Expansion:<\/strong> Entry into hepatology\/cholestatic disease; complements GI portfolio<\/li>\n\n\n\n<li><strong>Global Commercial Infrastructure:<\/strong> Leverage European strength (Italy-based) for PBC pruritus market development<\/li>\n\n\n\n<li><strong>Near-Term Revenue:<\/strong> FDA approval anticipated weeks post-deal; immediate U.S. launch capability<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Market Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>PBC Prevalence<\/strong><\/td><td>~130,000 diagnosed U.S. patients; 65% experience moderate-severe pruritus<\/td><\/tr><tr><td><strong>Standard of Care<\/strong><\/td><td>UDCA first-line; ~40% inadequate response; pruritus often refractory<\/td><\/tr><tr><td><strong>Competitive Threats<\/strong><\/td><td>Gilead&#8217;s seladelpar (PPAR\u03b4 agonist) approved 2024; obeticholic acid (OCALIVA) delisted from China; IBAT class emerging<\/td><\/tr><tr><td><strong>IBAT Class<\/strong><\/td><td>Linerixibat first-to-market potential; maralixibat (Mirum) approved for Alagille syndrome pruritus (pediatric)<\/td><\/tr><tr><td><strong>Pricing Power<\/strong><\/td><td>Orphan indication supports premium pricing; U.S. annual cost anticipated $50,000-75,000<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-timeline-amp-launch-outlook\">Regulatory Timeline &amp; Launch Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Date<\/th><th>Status<\/th><\/tr><\/thead><tbody><tr><td><strong>PDUFA Target<\/strong><\/td><td>March\u202f24,\u202f2026<\/td><td>FDA decision pending<\/td><\/tr><tr><td><strong>Deal Close<\/strong><\/td><td>Post-FDA approval<\/td><td>Alfasigma assumes global rights<\/td><\/tr><tr><td><strong>EU Filing<\/strong><\/td><td>2026<\/td><td>MAA submission anticipated<\/td><\/tr><tr><td><strong>Commercial Launch<\/strong><\/td><td>Q2\u202f2026 (U.S.)<\/td><td>Alfasigma U.S. infrastructure activation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding FDA approval timelines, commercial launch execution, and sales milestone achievement for linerixibat. Actual results may differ due to regulatory decisions, competitive dynamics with PPAR agonists, and pricing negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2936,278,184,914],"class_list":["post-59182","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-alfasigma","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59182\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-10T08:25:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-10T08:25:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value\",\"datePublished\":\"2026-03-10T08:25:29+00:00\",\"dateModified\":\"2026-03-10T08:25:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182\"},\"wordCount\":424,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Alfasigma\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59182#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59182\",\"name\":\"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-10T08:25:29+00:00\",\"dateModified\":\"2026-03-10T08:25:30+00:00\",\"description\":\"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59182\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59182","og_locale":"en_US","og_type":"article","og_title":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value","og_description":"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.","og_url":"https:\/\/flcube.com\/?p=59182","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-10T08:25:29+00:00","article_modified_time":"2026-03-10T08:25:30+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59182#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59182"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value","datePublished":"2026-03-10T08:25:29+00:00","dateModified":"2026-03-10T08:25:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59182"},"wordCount":424,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Alfasigma","GlaxoSmithKline","GSK","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59182#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59182","url":"https:\/\/flcube.com\/?p=59182","name":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-10T08:25:29+00:00","dateModified":"2026-03-10T08:25:30+00:00","description":"GlaxoSmithKline (GSK, NYSE:\u202fGSK) and Alfasigma S.p.A. announced a licensing agreement granting Alfasigma exclusive global rights to linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor for cholestatic pruritus (itch) associated with primary biliary cholangitis (PBC). The deal delivers $300\u202fmillion upfront to GSK, with $100\u202fmillion FDA approval milestone anticipated pre-close (PDUFA date: March\u202f24,\u202f2026), and up to $690\u202fmillion total value including regulatory, sales milestones, and tiered double-digit royalties.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59182"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Licenses Linerixibat to Alfasigma for $300\u202fMillion Upfront \u2013 IBAT Inhibitor Targets PBC Pruritus with $690\u202fMillion Total Deal Value"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59182"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59182\/revisions"}],"predecessor-version":[{"id":59183,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59182\/revisions\/59183"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}